 |
 |
Nordic Biotech is a specialized biotech venture capital fund focusing primarily on Nordic Countries but also
rest of EU. The investment focus is mainly early stage, but also spin-outs and restructurings. The team behind
Nordic Biotech has extensive experience in biotech investment and has co-founded or invested in a series of
biotech successes, such as Genmab A/S, Profound Pharma A/S, Biomarin Inc., Zealand Pharma A/S and many others
over the last decade.
Nordic Biotech is affiliated with a strong advisory board consisting of worldwide based
pharmaceutical research and development executives. Nordic Biotech has a high-class investor base, amongst
them: H. Lundbeck A/S, Danish Growth Fund, Biotechnology Value Fund L.P., The European Investment Fund, HBM
Bioventures and Wallenberg Capital.
BioScience Managers Limited is an investment advisor and manager to multiple venture capital
funds. It is the
fund advisor for the 123MultiNova Europe Fund for life science investments in Europe in the areas of human
therapeutics, medical devices and diagnostics.
BML also manages the BML International Maple Leaf Fund, a fund
backed by the Ontario Teachers Pension Plan Board to invest in Canadian life science companies. BML
additionally advises Seroba BioVentures Limited ("Seroba") on its investments in life science companies in
Ireland.
123venture.com is an independent fund management firm based in Paris. 123Ventures provides
private investors
with unique access to the best private equity teams (venture capital, development capital, LBO) in Europe
through its fund of funds and multi-manager funds.
www.catscience.dk
|
